Ποια είναι η τιμή για Paion AG (PA8)

Η τιμή για Paion AG (PA8) είναι $0.42701586

Ποια είναι η κεφαλαιοποίηση αγοράς για Paion AG (PA8)

Η κεφαλαιοποίηση αγοράς για Paion AG (PA8) είναι $3.21M

Paion AG (PA8) Τιμή και Κεφαλαιοποίηση Αγοράς

Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.

Η τιμή για PA8	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$724,341 $3.21M	NVDA	$5.452T	+169,628,401.86%
$596,549 $3.21M	AAPL	$4.490T	+139,701,637.43%
$553,022 $3.21M	GOOG	$4.162T	+129,508,336.60%
$488,443 $3.21M	MSFT	$3.676T	+114,385,004.48%
$376,401 $3.21M	AMZN	$2.833T	+88,146,714.96%

Η τιμή για PA8

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$724,341 $3.21M